Janel Corporation Reports $56M Revenue with 9.1% Growth Driven by Acquisitions

Janel Corporation reported a consolidated revenue of $56.0 million for the three months ended December 31, 2025, marking a 9.1% increase from $51.4 million in the same period last year. The growth was primarily driven by the inclusion of revenues from recent acquisitions, particularly in the Logistics segment, which generated $50.8 million, up from $46.1 million a year earlier. Gross profit also increased to $18.1 million, compared to $15.1 million in the prior year, although income from operations fell to $978,000 from $1.2 million, attributed to higher operating expenses and lower performance in the Life Sciences and Manufacturing segments.

The company experienced notable changes in its financial metrics compared to the previous fiscal period. Net income attributable to Janel Corporation was $419,000, or $0.58 per diluted share, down from $659,000, or $0.55 per diluted share, in the prior year. The decrease in net income was largely due to increased corporate expenses and lower income from operations in the Life Sciences and Manufacturing segments. Adjusted operating income for the quarter was $2.0 million, slightly down from $2.0 million in the same period last year.

Strategically, Janel has been active in expanding its business through acquisitions. In October 2025, the company completed a significant acquisition of Rubicon Technology, increasing its ownership stake to approximately 91%. This acquisition is expected to enhance Janel's capabilities in the manufacturing segment. Additionally, the company acquired a majority stake in Interlog USA, Inc. in September 2025, further bolstering its Logistics segment. These acquisitions are part of Janel's strategy to grow through both organic means and strategic investments in complementary businesses.

Operationally, Janel's Logistics segment showed strong performance with a gross profit margin increase to 28.2%, up from 24.7% in the previous year, driven by improved freight rates and operational efficiencies. However, the Life Sciences segment reported a decline in income from operations, primarily due to increased costs associated with the Biosensis acquisition. The Manufacturing segment, which now includes Rubicon, reported a decrease in revenue and gross profit, reflecting challenges in sales volumes and product mix.

Looking ahead, Janel Corporation aims to continue its growth trajectory through strategic acquisitions and operational improvements. The company is focused on enhancing its service offerings and expanding its market presence, particularly in the Logistics and Life Sciences sectors. Management remains optimistic about the potential for future growth, despite the challenges posed by market conditions and integration costs associated with recent acquisitions.